Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

Figure 2

Effect of single-agent motesanib on various NSCLC xenograft tumor models. Tumor volume (top) and body weight (bottom) over time in response to single-agent motesanib. (A) A549 tumors treated with vehicle or motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BID for 17 days. ‡P < 0.01 regression; day 21 vs day 38. (B) Calu-6 tumors treated with vehicle or motesanib 37.5 mg/kg BID, 75 mg/kg QD, or 75 mg/kg BID for 17 days. (C) NCI-H358 tumors treated with vehicle or motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BID for 21 days. §P < 0.0001 regression; day 4 vs day 25. (D) NCI-H1299 tumors treated with vehicle or motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BID for 21 days. (E) NCI-H1650 tumors treated with vehicle or motesanib 15 mg/kg BID, 50 mg/kg BID, or 75 mg/kg BID for 35 days. Data are expressed as mean ± SE. For all panels, *P < 0.05 vs vehicle, †P < 0.0001 vs vehicle.

Back to article page

Molecular Cancer

ISSN: 1476-4598